Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. It is available as a tablet.
Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
Zafirlukast is marketed by AstraZeneca with the brand names Accolate, Accoleit, and Vanticon. It was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Italy, Spain, Canada, Brazil and China.
More on [ Zafirlukast ]

Accolate - Prescribing information for US residents in PDF format.[Acrobat Reader required]
Accolate (Zafirlukast) - Information from DrugDigest on dosage, usage, side effects, and interactions.
Accolate - AstraZeneca - Official pharmaceutical website for Accolate (zafirlukast), a nonsteroidal tablet for the prevention and continuous treatment of asthma in adults and children 5 years of age and older; available only by prescription.
Meta Description: [ AstraZeneca, one of the world's leading pharmaceutical companies providing innovative prescription medicines, is dedicated to making healthcare a more personal experience for patients. ]
MedlinePlus: Zafirlukast - Features information about dosage, usage, warnings, and side effects.
Meta Description: [ Zafirlukast ]
| FDA Studying Potential Safety Issues with Several Drugs | |